All Articles

Explains why higher cord blood and tissue stem cell yields improve transplant success, expand treatment options, and support future regenerative therapies.

How placental tissue—rich in MSCs, hAECs, and growth factors—complements cord blood for wound healing, orthopedics, neurology, and long-term banking.

MRI, PET/CT, and AI enable noninvasive, real-time tracking of transplanted stem cells—revealing viability, inflammation, and early indicators of success in autoimmune therapies.

Overview of clinical trial results for stem cell therapy in orthopedic injuries: efficacy, safety, delivery methods, sources, and regulatory challenges.

Clear overview of cord blood, cord tissue, placenta, and amniotic fluid stem cells — collection, storage, medical uses, and ongoing clinical research.

Practical ways to offset private cord blood banking costs — HSAs/FSAs, insurance, employer reimbursements, tax deductions, and flexible payment plans.

A clear comparison of AABB and FACT cord blood accreditation — scope, update cycles, clinical vs. technical focus, shared safety requirements, and verification tips.

Cord blood offers faster access and lower chronic GVHD but slower engraftment and higher early infection risk than bone marrow.

Umbilical cord hUC-MSCs can regenerate cartilage, lower inflammation, and improve joint function for osteoarthritis with low immune risk and clinical evidence.